Your SlideShare is downloading. ×
Tabalumab (Rheumatoid Arthritis) Forecast and Market Analysis
Tabalumab (Rheumatoid Arthritis) Forecast and Market Analysis
Tabalumab (Rheumatoid Arthritis) Forecast and Market Analysis
Tabalumab (Rheumatoid Arthritis) Forecast and Market Analysis
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Tabalumab (Rheumatoid Arthritis) Forecast and Market Analysis

85

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
85
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Tabalumab (Rheumatoid Arthritis) Forecast and MarketAnalysisReport Details:Published:November 2012No. of Pages: 45Price: Single User License – US$6995Tabalumab (Rheumatoid Arthritis) Forecast and Market AnalysisSummaryGlobalData has released its new PharmaPoint Drug Evaluation report, Tabalumab (RheumatoidArthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with theNovember 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaitingapproval such as: Eli Lilly’s anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ’sSYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt todislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven oncethey enter the market.Eli Lilly and Company’s tabalumab is poised to become the first anti-BAFF mAb for the treatmentof RA. Tabalumab binds and inhibits the activity of soluble and cell surface-bound BAFF whichthen decreases the activity, proliferation, and survival of B cells. It reduces levels of B cellsresponsible for autoantibody production in RA without obliterating the bodys ability to generateimmunoglobulins. Tabalumab is currently in Phase III in the US and EU and in Phase I in Japan.Scope- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatmentguidelines as well as an overview on the competitive landscape.- Detailed information on Tabalumab including product description, safety and efficacy profiles aswell as a SWOT analysis.- Sales forecast for Tabalumab for the top eight countries from 2011 to 2022.- Sales information covered for the US, France, Germany, the UK, Italy, Spain, Japan andAustralia.Reasons to buy
  • 2. - Understand and capitalize by identifying products that are most likely to ensure a robust return- Stay ahead of the competition by understanding the changing competitive landscape forrheumatoid arthritis.- Effectively plan your M&A and partnership strategies by identifying drugs with the most promisingsales potential- Make more informed business decisions from insightful and in-depth analysis of Tabalumabperformance- Obtain sales forecast for Tabalumab from 2011 to 2022 in (the US, France, Germany, the UK,Italy, Spain, Japan and Australia)Get your copy of this report @http://www.reportsnreports.com/reports/213176-tabalumab-rheumatoid-arthritis-forecast-and-market-analysis.htmlMajor points covered in Table of Contents of this report include1 Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 52 Introduction 62.1 Catalyst 62.2 Related Reports 73 Disease Overview 93.1 Etiology and Pathophysiology 93.1.1 Etiology 93.1.2 Pathophysiology 93.1.3 Prognosis 123.1.4 Quality of Life 123.2 Symptoms 134 Disease Management 144.1 Overview 144.2 Diagnosis 144.3 Treatment 175 Competitive Assessment 215.1 Overview 215.2 Strategic Competitor Assessment 216 Opportunity and Unmet Need 236.1 Overview 236.2 Unmet Needs 246.2.1 More rheumatologists in the field and physician knowledge of the disease 246.2.2 More cost-effective therapies through oral formulation and biosimilars 246.2.3 The development of predictive tests and discovery of biomarkers 24
  • 3. 6.2.4 The discovery of curative therapies 256.2.5 Improved drug safety and efficacy profiles 256.3 Gap Analysis 266.4 Opportunities 276.4.1 Predictive tools for diagnosis and treatment 276.4.2 Target specificity 277 Pipeline Assessment 287.1 Overview 287.2 Promising Drugs in Clinical Development 298 Tabalumab (LY2127399) 318.1 Overview 318.2 Efficacy 328.3 Safety 328.4 Dosing and Formulation 328.5 Potential Clinical Positioning 338.6 Potential Commercial Positioning 338.7 Pricing and Reimbursement 338.8 SWOT Analysis 338.9 Forecast 349 Appendix 359.1 Abbreviations 359.2 Bibliography 379.3 Methodology 409.4 Forecasting Methodology 409.4.1 Diagnosed Rheumatoid Arthritis Patients 409.4.2 Percent Drug-treated Patients 409.4.3 General Pricing Assumptions 419.4.4 Pricing of Pipeline agents 429.5 Physicians and Specialists Included in this Study 429.6 Primary Research - Prescriber Survey 439.7 About the Authors 439.7.1 Analysts 439.7.2 Global Head of Healthcare 449.8 About GlobalData 459.9 Contact Us 459.10 Disclaimer 451.1 List of TablesTable 1: Symptoms of Rheumatoid Arthritis 13Table 2: Treatment Guidelines for Rheumatoid Arthritis 17Table 3: Top Three Biologics Prescribed for Moderate-Severe Rheumatoid Arthritis by Market 20Table 4: Treatment Guidelines for Rheumatoid Arthritis 22
  • 4. Table 5: Overall Unmet Needs - Current Level of Attainment 23Table 6: Clinical Unmet Needs - Gap Analysis, 2012 26Table 7: Rheumatoid Arthritis - Phase Pipeline, 2012 29Table 8: Comparison of Therapeutic Classes in Development for RA, 2012 30Table 9: Product Profile - Tabalumab 31Table 10: ACR Responses and DAS28 Scores for Tabalumab vs. Placebo at Week 16 32Table 11: Tabalumab SWOT Analysis, 2012 33Table 12: Global Sales Forecasts ($m) for Tabalumab 34Table 13: Physicians Surveyed, By Country 431.2 List of FiguresFigure 1: Healthy and Arthritic Joint with Rheumatoid Arthritis 9Figure 2: Rheumatoid Arthritis Biologic Drug Targets 11Figure 3: Diagnosis Criteria for Rheumatoid Arthritis Based on 2010 ACR/EULAR Criteria PointSystem 16Figure 4: Severity of Rheumatoid Arthritis 16Figure 5: Biologic Treatment Flow Based on Updated 2012 ACR Treatment Recommendations*19Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2012-2022 29Contact: sales@reportsandreports.com for more information.

×